Female contraceptives are numerous and varied, but male options are limited. There’s the common condom and at the other end of the spectrum is the extreme surgical solution in vasectomy. A new type of contraceptive is supposed to change all of that by being safe, is 98% effective, and only costs $10. Unfortunately, it seems big drug companies have expressed minimal interest in the revolutionary medical discovery.
The contraceptive in question is called Reversible Inhibition of Sperm Under Guidance (RISUG) and it was made by Indian biomedical engineer Sujoy Guha, Futurism reports. It’s revolutionary in that in not only provides men with a safe, effective, and affordable way to be reproductively responsible, it also takes a lot of the pressure off women.
For decades, women had the substantial burden of making sure that they didn’t get pregnant and many of them suffered greatly due to some of the side-effects. In contrast, men only had to make sure to bring a condom and the only problem with that option is the reduced sensation during sexual intercourse. The disparity could not be clearer in that scenario alone.
With RISUG, Guha created something that should have been a financial hit. Unfortunately, he found that big pharma was just not willing to risk spending potentially hundreds of millions of dollars on a single male contraceptive.
As to how the contraceptive works, it’s basically like a filter that is injected into the tracks that allow semen and sperm to travel from the scrotum to the urethra. It involves only one shot to let the semen through while preventing sperm cells from exiting. The result is sexual pleasure without the stress.
Fortunately, the birth control method is in its final stages in testing in India, Bloomberg recently reported. Once it is given the green light, it could hit the market in less than two years.


Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 



